ADYX
vs
S&P 500
ADYX
S&P 500
Over the past 12 months, ADYX has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +12% growth.
Stocks Performance
ADYX vs S&P 500
Performance Gap
ADYX vs S&P 500
Performance By Year
ADYX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Adynxx Inc
Glance View
Adynxx, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The firm is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
